Your abstract must conform to the following guidelines:

 

Abstract Categories

For your submission, you are required to select one of the following categories:

• Adult Congenital

• Aorta & Aortic Arch

• Aortic Root

• Aortic Valve

• Atrial Fibrillation

• Coronary Artery Disease

• Heart Failure/VADs

• Mitral Valve

• Pediatric Congenital

• Quality and Outcomes Initiatives

• Tricuspid Valve

​

 

 

The EACTS way of abstract submission is by a short PowerPoint presentation. The reason is that we think it is simpler to submit an abstract in this way and it will also a allow a faster and better review process. 

Please follow the instructions carefully. A presentation which is understandable and follows the instructions is much more likely to be accepted for presentation at the meeting. 

It is mandatory to download and use the 2024 EACTS/STS/LACES Abstract Template.  Only this template is accepted and only a maximum of 7 slides is allowed! 

​

• Slide 1: Title & ID – The first slide contains the Title of the presentation and also the Abstract ID from the online submission site 
  Do not use the “Enter” button in your title. This action will add hard returns, which are not allowed. 
  Do not use abbreviations in the title. Abbreviations may be used in the following slides.
  Do not end the title with a period (.) 
  Do not use quotation marks in a title (” “) 
  The title must not be CAPS. Do not bold, italicize, underline, superscript or subscript any items in the title. 

• Slide 2: Background and study objective (maximum 8 bullet points) 

• Slide 3: Patients (if applicable); maximum 8 bullet points 

• Slide 4: Methods (maximum 8 bullet points) 

• Slide 5: Results 1 (can include Text, Table, Graph, image, but no videos) 

• Slide 6: Results 2 (if necessary, a second slide with results is allowed) 

• Slide 7: Conclusion (only text. maximum 5 bullet points) 

​​

Other:

• No slides are allowed to contain any reference to the hospital, university or author.  Do not include authors in the title. If you enter authors in the title, your presentation will be rejected. Do not include institutions in the title. If you enter institutions in the title, the presentation will be rejected. 

• The minimum font size 21 pt. 

• When you have finished your presentation, please save your presentation first as a PPT or PPTX file (depending on which version of PowerPoint you use) for your own reference. 

• After this use the option in PowerPoint to save your file as a PDF file. Click “File”, choose the option “Save as”, choose the location where you want to save the file, type the File name – please use your Abstract Id as the file name and in the “Save as type” list, click PDF (*.pdf). Fig 1. 

• Choose the smaller file size , click “Minimum size (publishing online). Fig. 2. 

• The PDF file is uploaded through the abstract submission site, not the PPT or PPTX file. 

• The institution name, state, and email address information of the presenting author and all co-authors must be provided.

• When percentages are used, the absolute numbers of derivation must be stated.

• To ensure fairness, abstracts are read and graded in a blinded fashion with no references to authors or institutions.  Abstracts are reviewed by peer reviewers based on scientific merit, originality, and practice gaps identified.

 

General 

• Only abstracts submitted using the online system will be considered for presentation.

• Only authors (and not their assistants) may complete submissions; authors will be responsible for the information provided.

• The submitting author must provide accurate email addresses of all co-authors, and must attest that

  • (a) all co-authors of the abstract have granted consent for the material to be submitted for presentation, and

  • (b) that the submitting author has been granted the right by all co-authors to act on their behalf.

• For the submitted abstract, each co-author will be asked to complete a disclosure form.

• EACTS/STS/LACES  reserves the right to withdraw any abstract at any time.

• All abstracts must be submitted in English. If selected for oral presentation during the Conference, the author may present in either English or Spanish.

• If an abstract is not accepted as an oral presentation, it may be accepted as a scientific e-Poster presentation instead. The final determination on format is at the discretion of the Programme Directors. Scientific posters must be displayed in English.

• The person listed as the presenting author for each abstract must attend the EACTS/STS/LACES  Latin America Cardiovascular Surgery Conference. In the event that a change of presenting author must be made after abstract submission, EACTS must be notified in writing. NOTE: The replacement presenter must be a co-author of the abstract.

• Once an abstract has been accepted, additional authors may not be added.

• Abstract content must be based upon the best available evidence and should not promote any health care device, drug, other product or service.

• If the presenter has any relationship posing a conflict or potential conflict relevant to his or her session, he or she may not make any recommendations regarding relevant products or services as part of that session.

• If your abstract is selected, you will be asked to present it as either an oral presentation during a specific session or within a moderated  e-Poster Session.

• The Programme Committee will review your abstract, and you will be notified of its decision in September 2024. Results will be sent only to the presenting author listed on the abstract via email. Only the presenting author will be notified. We kindly ask that the presenting author communicate this information with all co-authors.

 

Disclosure Information

Conflict of interest disclosure (if relevant) is required before an abstract will be accepted for consideration. If a potential conflict of interest exists, be sure to include the name of the organisation/company and the nature of the potential conflict.

 

• Each author must submit her/his individual disclosure when completing the abstract submission.

• It is the responsibility of the submitting author to identify each co-author on the abstract. Upon submission of the abstract, an email will be sent to each co-author, who will then be responsible for submitting her/his individual disclosure.

• If commercial relationship information and FDA disclosures are not received from all co-authors by the abstract submission deadline, the abstract will not be considered for review.

• For live presentations, all relationships with commercial interests and FDA disclosures, as defined in the Education Disclosure Policy (below), must be stated orally to the audience at the beginning of each presentation. In addition, a slide at the beginning of the PowerPoint presentation must be used to reveal the nature of the disclosure(s). This commercial relationship and FDA disclosure information will be noted in published materials. Speakers are required to communicate that they have nothing to disclose, if that is the case.

• For scientific poster presentations, all relationships with commercial interests must be displayed on each scientific e-Poster along with any FDA disclosures.

 

Education Disclosure Policy  

As a sponsor of continuing medical education accredited by the Accreditation Council for Continuing Medical Education (ACCME), The Society of Thoracic Surgeons requires that any individual who is in a position to control the content of an educational activity must disclose all relationships with commercial interests (including known relationships of his or her immediate family, department, and partners). The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.” The question of whether a disclosed conflict situation could represent undue influence on the educational activity by a commercial interest or whether the disclosed information is sufficient to consider an abstract, presentation, or other educational enduring material to represent potentially biased information must be resolved prior to an individual’s involvement in EACTS/STS/LACES  educational programming.

 

Required disclosures include (1) a financial interest of any amount (e.g., through ownership of stock, stock options, or bonds) (2) the receipt of any amount of cash, goods or services within the current 12-month period (e.g., through research grants, employment, consulting fees, royalties, travel, or gifts) or (3) a nonremunerative position of influence (e.g., as officer, director, trustee or public spokesperson). EXCLUDED from this disclosure requirement are blind trusts or other passive investments such as mutual funds. In the case of a financial or other relationship disclosure, the company, product/service, and the specific nature of the relationship must be noted. Disclosure is mandatory for any person involved in the planning, management, presentation, and/or evaluation of EACTS/STS/LACES  educational activities.

 

Failure to disclose all relationships with commercial interests disqualifies the individual from being a planning committee member, a teacher, or an author of educational materials, and this individual cannot have any responsibility for the development, management, presentation, or evaluation of EACTS/STS/LACES educational activities. This requirement is intended neither to imply any impropriety of such relationships nor to prejudice any individual planner, presenter or author. It is merely to identify such relationships through full disclosure, and to allow EACTS/STS/LACES  to assess and resolve potential influences on the educational activity prior to the planning and implementation of an educational activity. If no relationships with commercial interests exist, the individual must indicate this on the disclosure form.

 

Additionally, the fact that the presentation, paper, or other educational product describes (a) the use of a device, product, or drug that is not FDA approved or (b) an off-label use of an approved device, product, or drug must also be disclosed. This requirement has been adopted in response to FDA policy and case law involving medical societies and is not intended to prohibit or inhibit independent presentation or discussion regarding the uses of devices, products, and drugs as described in (a) or (b) above.

 

For live presentations, all disclosures must be stated orally and on a slide at the beginning of the presentation and will be noted in published material related to the activity. Slides, handouts, and other materials utilized as part of an educational activity cannot contain any advertising, trade names or a product group message. Speakers are required to disclose that they have nothing to disclose if this is the case.

​

 

Withdrawal of an Abstract

To withdraw an abstract, the presenter must notify EACTS in writing. Please email EACTS at registration@eacts.co.uk and include the title of the abstract.